Skip to content

Cognitive therapy for generalised anxiety in youth

Cognitive therapy for generalised anxiety disorder in children and young people: a pilot randomised controlled trial and qualitative investigation of their experience of treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN50951795
Enrollment
40
Registered
2010-06-30
Start date
2009-01-01
Completion date
Unknown
Last updated
2019-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Mental Health Research Network

Interventions

Intervention: cognitive therapy for GAD as developed by Dugas and Robichaud but adapted for use with pre-pubertal children and adolescents. Treatment will be weekly, individual and child-focused.

Sponsors

King's College London (KCL) (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Children/young people aged 10 - 18 years, either sex 2. Diagnosis of GAD according to Diagnostic and Statistical Manual of Mental Disorders, version 4 (DSM-IV) criteria 3. Consecutively referred to a National and Specialist children's anxiety clinic (if they give informed consent) 4. Participants with a comorbid Axis 1 diagnosis will be included provided GAD is the primary disorder in need of treatment

Exclusion criteria

Exclusion criteria: 1. Psychosis or learning difficulties (estimated intelligence quotient [IQ] below 70) or autistic spectrum disorder 2. Another mental health problem other than GAD that is more in need of treatment at the time of referral (such as severe depression)

Design outcomes

Primary

MeasureTime frame
GAD diagnostic status, measured with DSM-IV at entry to the trial (pre-treatment), post-treatment (10 weeks) or post-wait/self-monitoring

Secondary

MeasureTime frame
1. Worry frequency, measured with Penn State Worry Questionnaire for Children (PSWQ-C) 2. Quality of life as measured by the Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire Measured at baseline, mid-treatment (5 weeks), end of treatment (10 weeks) and at 3-month follow up assessment.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026